Skip to main content
New portfolio addition for
EDS in Narcolepsy and OSA
     view press release


a multi-mechanistic approach to treating migraine

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC™ (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan.

AXS-07 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.

Mechanism of action of AXS-07

clinical and regulatory

AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.